178 related articles for article (PubMed ID: 34521110)
1. Blood-brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study.
Huang SS; Pavenski K; Lee TY; Jurkiewicz MT; Bharatha A; Thiessen JD; St Lawrence K; Théberge J; Mandzia J; Barth D; Licht C; Patriquin CJ
Blood Adv; 2021 Oct; 5(20):4211-4218. PubMed ID: 34521110
[TBL] [Abstract][Full Text] [Related]
2. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
Tse B; Buchholz M; Pavenski K
Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
[TBL] [Abstract][Full Text] [Related]
3. Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) - cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom.
Holmes S; Podger L; Bottomley C; Rzepa E; Bailey KMA; Chandler F
Hematology; 2021 Dec; 26(1):465-472. PubMed ID: 34238132
[TBL] [Abstract][Full Text] [Related]
4. Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura.
Joffre J; Raia L; Urbina T; Bonny V; Gabarre P; Missri L; Baudel JL; Coppo P; Guidet B; Maury E; Ait-Oufella H
Crit Care; 2023 Mar; 27(1):116. PubMed ID: 36944989
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age.
Rottenstreich A; Dor S; Keren-Politansky A; Sarig G; Nadir Y; Ellis M; Spectre G; Kirgner I; Pikovsky O; Arad A; Dann EJ; Kalish Y
J Thromb Thrombolysis; 2021 Jan; 51(1):187-193. PubMed ID: 32388825
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.
Lu R; Sui J; Zheng XL
Blood Adv; 2020 Nov; 4(21):5378-5388. PubMed ID: 33141886
[TBL] [Abstract][Full Text] [Related]
7. Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.
Yue C; Su J; Fan X; Song L; Jiang W; Xia J; Shi T; Zhang X; Li X
Orphanet J Rare Dis; 2020 Aug; 15(1):225. PubMed ID: 32859237
[TBL] [Abstract][Full Text] [Related]
8. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.
Pascual-Izquierdo C; Del Rio-Garma J; de la Rubia J; Viejo A; Mingot E; Cid J; Solanich X; Fernández-Sojo J; Martín-Sánchez J; Hernández L; García-Gala JM; Alonso N; González V; Oliva A; Gómez-Seguí I; Goterris R; Guerra L; García-Candel F; Fernández-Docampo M; Antelo ML; Salgado-Barreira Á; Salinas R;
J Clin Apher; 2021 Aug; 36(4):563-573. PubMed ID: 33780553
[TBL] [Abstract][Full Text] [Related]
9. Hemostatic Profile and Serological Response of Patients with Immune Thrombotic Thrombocytopenic Purpura after Receiving BNT162b2 Vaccine: A Prospective Study.
Schieppati F; Russo L; Gamba S; Galimberti E; Giaccherini C; Tartari CJ; Bolognini S; Verzeroli C; Ticozzi C; Barcella L; Marchetti M; Falanga A
Thromb Haemost; 2023 Oct; 123(10):945-954. PubMed ID: 37172940
[TBL] [Abstract][Full Text] [Related]
10. Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura.
Brodsky MA; Sukumar S; Selvakumar S; Yanek L; Hussain S; Mazepa MA; Braunstein EM; Moliterno AR; Kickler TS; Brodsky RA; Cataland SR; Chaturvedi S
Am J Hematol; 2021 Dec; 96(12):1587-1594. PubMed ID: 34460124
[TBL] [Abstract][Full Text] [Related]
11. Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.
Prevel R; Roubaud-Baudron C; Gourlain S; Jamme M; Peres K; Benhamou Y; Galicier L; Azoulay E; Poullin P; Provôt F; Maury E; Presne C; Hamidou M; Saheb S; Wynckel A; Servais A; Girault S; Delmas Y; Chatelet V; Augusto JF; Mousson C; Perez P; Halimi JM; Kanouni T; Lautrette A; Charvet-Rumpler A; Deligny C; Chauveau D; Veyradier A; Coppo P
Blood; 2019 Dec; 134(24):2209-2217. PubMed ID: 31530564
[TBL] [Abstract][Full Text] [Related]
12. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
Mazepa MA; Park YA; Raval JS
Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
[TBL] [Abstract][Full Text] [Related]
13. Identification of Biomarkers in Patients with Thrombotic Thrombocytopenic Purpura Presenting with Large and Small Ischemic Stroke.
Lin C; Memon R; Sui J; Zheng XL
Cerebrovasc Dis Extra; 2021; 11(1):29-36. PubMed ID: 33601375
[TBL] [Abstract][Full Text] [Related]
14. [Endothelial dysfunction in thrombotic thrombocytopenic purpura: therapeutic perspectives].
Prevel R; Roubaud-Baudron C; Tellier E; Le Besnerais M; Kaplanski G; Veyradier A; Benhamou Y; Coppo P;
Rev Med Interne; 2021 Mar; 42(3):202-209. PubMed ID: 33455838
[TBL] [Abstract][Full Text] [Related]
15. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
Roose E; Schelpe AS; Tellier E; Sinkovits G; Joly BS; Dekimpe C; Kaplanski G; Le Besnerais M; Mancini I; Falter T; Von Auer C; Feys HB; Reti M; Rossmann H; Vandenbulcke A; Pareyn I; Voorberg J; Greinacher A; Benhamou Y; Deckmyn H; Fijnheer R; Prohászka Z; Peyvandi F; Lämmle B; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
Blood; 2020 Jul; 136(3):353-361. PubMed ID: 32356859
[TBL] [Abstract][Full Text] [Related]
16. Post-traumatic stress disorder and quality of life alterations in survivors of immune-mediated thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome.
Azoulay E; Souppart V; Kentish-Barnes N; Benhamou Y; Joly BS; Zafrani L; Joseph A; Canet E; Presne C; Grall M; Zerbib Y; Provot F; Fadlallah J; Mariotte E; Urbina T; Veyradier A; Coppo P
J Crit Care; 2023 Aug; 76():154283. PubMed ID: 36931181
[TBL] [Abstract][Full Text] [Related]
17. Deleterious neurological impact of diagnostic delay in immune-mediated thrombotic thrombocytopenic purpura.
Renaud A; Caristan A; Seguin A; Agard C; Blonz G; Canet E; Eveillard M; Godmer P; Graveleau J; Lecouffe-Desprets M; Maisonneuve H; Perrin F; Hamidou M; Néel A
PLoS One; 2021; 16(11):e0260196. PubMed ID: 34797873
[TBL] [Abstract][Full Text] [Related]
18. Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.
Kangro K; Roose E; Joly BS; Sinkovits G; Falter T; von Auer C; Rossmann H; Reti M; Voorberg J; Prohászka Z; Lämmle B; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
Blood Adv; 2021 Sep; 5(17):3427-3435. PubMed ID: 34495312
[TBL] [Abstract][Full Text] [Related]
19. Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura.
Garraud O; Malot S; Herbrecht R; Ojeda-Uribe M; Lin JS; Veyradier A; Payrat JM; Liu K; Corash L; Coppo P
Transfus Apher Sci; 2019 Dec; 58(6):102665. PubMed ID: 31740165
[TBL] [Abstract][Full Text] [Related]
20. Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship.
Selvakumar S; Liu A; Chaturvedi S
Front Med (Lausanne); 2023; 10():1137019. PubMed ID: 36926315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
